Sarilumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sarilumab" in English language version.

refsWebsite

Global rank English rank

5web.archive.org

1^st place

5nih.gov

4^th place

3europa.eu

68^th place

117^th place

3doi.org

2^nd place

1canada.ca

1,712^th place

1,063^rd place

1hpfb-dgpsa.ca

low place

1ama-assn.org

3,257^th place

3,398^th place

1regeneron.com

low place

1semanticscholar.org

11^th place

8^th place

1drugs.com

399^th place

333^rd place

1sanofi.com

low place

1modernmedicine.com

low place

1stanford.edu

179^th place

183^rd place

1bostonglobe.com

553^rd place

334^th place

1bbc.co.uk

8^th place

10^th place

ama-assn.org

"Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab" (PDF). ama-assn.org. American Medical Association.

bbc.co.uk

Roberts M (7 January 2021). "Two more life-saving Covid drugs discovered". BBC News. Retrieved 7 January 2021.

bostonglobe.com

Sanofi halts tests of arthritis drug for use as a COVID-19 treatment

canada.ca

"Arthritis". Health Canada. 8 May 2018. Retrieved 13 April 2024.

doi.org

Boyce EG, Rogan EL, Vyas D, Prasad N, Mai Y (February 2018). "Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis". Annals of Pharmacotherapy. 52 (8): 780–791. doi:10.1177/1060028018761599. PMID 29482351. S2CID 3580054.
Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. (May 2017). "Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial". Annals of the Rheumatic Diseases. 76 (5): 840–847. doi:10.1136/annrheumdis-2016-210310. PMC 5530335. PMID 27856432.
Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. (June 2015). "Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study". Arthritis & Rheumatology. 67 (6): 1424–37. doi:10.1002/art.39093. PMID 25733246.

drugs.com

Drugs.com: Sarilumab Monograph. Accessed 29 November 2017.

europa.eu

ema.europa.eu

"Kevzara EPAR". European Medicines Agency (EMA). 23 June 2017. Retrieved 26 August 2024.
"Kevzara: Authorisation details". European Medicines Agency. Archived from the original on 27 September 2017. Retrieved 28 September 2017.
"Kevzara: EPAR – Product Information" (PDF). European Medicines Agency. 26 September 2017. Archived from the original (PDF) on 18 June 2018. Retrieved 29 November 2017.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Regulatory Decision Summary for Kevzara". Drug and Health Products Portal. 12 January 2017. Retrieved 13 April 2024.

modernmedicine.com

formularyjournal.modernmedicine.com

Walker T. "Sarilumab effective in broad range of RA patients: Study". Formulary Watch. Archived from the original on 21 November 2015.{{cite web}}: CS1 maint: overridden setting (link)

nih.gov

pubmed.ncbi.nlm.nih.gov

Boyce EG, Rogan EL, Vyas D, Prasad N, Mai Y (February 2018). "Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis". Annals of Pharmacotherapy. 52 (8): 780–791. doi:10.1177/1060028018761599. PMID 29482351. S2CID 3580054.
Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. (May 2017). "Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial". Annals of the Rheumatic Diseases. 76 (5): 840–847. doi:10.1136/annrheumdis-2016-210310. PMC 5530335. PMID 27856432.
Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. (June 2015). "Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study". Arthritis & Rheumatology. 67 (6): 1424–37. doi:10.1002/art.39093. PMID 25733246.

dailymed.nlm.nih.gov

"Kevzara- sarilumab injection, solution". DailyMed. 17 June 2024. Retrieved 26 August 2024.

ncbi.nlm.nih.gov

Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. (May 2017). "Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial". Annals of the Rheumatic Diseases. 76 (5): 840–847. doi:10.1136/annrheumdis-2016-210310. PMC 5530335. PMID 27856432.

regeneron.com

investor.regeneron.com

"Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis". regeneron.com (Press release). Paris & Tarrytown, New York: Regeneron. 12 July 2011.

sanofi.com

en.sanofi.com

"Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA). May 2013" (PDF). Archived from the original (PDF) on 19 January 2017. Retrieved 15 May 2013.

semanticscholar.org

api.semanticscholar.org

Boyce EG, Rogan EL, Vyas D, Prasad N, Mai Y (February 2018). "Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis". Annals of Pharmacotherapy. 52 (8): 780–791. doi:10.1177/1060028018761599. PMID 29482351. S2CID 3580054.

stanford.edu

med.stanford.edu

"More Information". Sarcoidosis Program. Archived from the original on 9 August 2019. Retrieved 9 August 2019.

web.archive.org

"Kevzara: Authorisation details". European Medicines Agency. Archived from the original on 27 September 2017. Retrieved 28 September 2017.
"Kevzara: EPAR – Product Information" (PDF). European Medicines Agency. 26 September 2017. Archived from the original (PDF) on 18 June 2018. Retrieved 29 November 2017.
"Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA). May 2013" (PDF). Archived from the original (PDF) on 19 January 2017. Retrieved 15 May 2013.
Walker T. "Sarilumab effective in broad range of RA patients: Study". Formulary Watch. Archived from the original on 21 November 2015.{{cite web}}: CS1 maint: overridden setting (link)
"More Information". Sarcoidosis Program. Archived from the original on 9 August 2019. Retrieved 9 August 2019.